Inclusion Criteria:

- Patients with metastatic colon or rectal cancer, progressing or relapsing after
first-line treatment;

- Women of childbearing potential must use adequate contraception up to at least 6
months after the last dose of bevacizumab.

Exclusion Criteria:

- Patients with metastatic colon or rectal cancer scheduled for a first-line systemic
treatment;

- Untreated brain metastases, spinal cord compression or primary brain tumours;

- Pregnant or lactating women;

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to study start;

- Treatment with any investigational drug, or participation in another investigational
study, within 30 days prior to enrollment.